AMSBIO, a global provider of gene editing and personalized medicine technologies, has launched a service for high throughput gene expression analysis.

Based on the NanoString nCounter platform, the service works with a large array of sample types, including formats such as formalin-fixed paraffin-embedded (FFPE), which have been difficult to analyse by more traditional quantitative PCR.

Using AMSBIO’s NanoString service you can simultaneously analyse expression of up to 800 mRNAs, miRNAs, DNA regions, or proteins. Simply send us your samples, and we will return a detailed gene expression report in less than two weeks. Researchers are able to choose from one of NanoString pre-made gene panels or design their own custom panel. Sample formats include RNA, cell and tissue lysates, whole blood, FFPE tissue, serum and plasma.

Maja Petkovic of AMSBIO, said “We are pleased to be able to offer NanoString services. NanoString instruments are costly, which has traditionally limited the access to this powerful technology for many researchers. Not only can we now offer the technology to all researchers, but we’ve also simplified the complex ordering process and can provide complete data analysis for our customers.”

For further information on the NanoString high throughput gene expression service please visit http://www.amsbio.com/nanostring-service.aspx or contact the company on +44-1235-828200/ +1-617-945-5033 / [email protected].

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.